Literature DB >> 20023120

Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration.

Célia Guilini1, Kyoji Urayama, Gulen Turkeri, Deniz B Dedeoglu, Hitoshi Kurose, Nadia Messaddeq, Canan G Nebigil.   

Abstract

Prokineticins are secreted peptides that activate two G protein-coupled receptors: PKR1 and PKR2. Prokineticins induce angiogenesis and fenestration, but the cognate receptors involved in these functions are unknown. We hypothesized a role for prokineticin receptor signaling pathways and expression profiles in determining the selective effects of prokineticins on coronary endothelial cells (H5V). Activation of the PKR1/MAPK/Akt signaling pathway stimulates proliferation, migration, and angiogenesis in H5V cells, in which PKR1 predominates over PKR2. PKR1 was colocalized with Galpha(11) and was internalized following the stimulation of these cells with prokineticin-2. Knock down of PKR1 or Galpha(11) expression in H5V cells effectively inhibited prokineticin-2-induced vessel formation and MAPK/Akt activation, indicating a role for PKR1/Galpha(11) in this process. However, in conditions in which PKR2 predominated over PKR1, these cells displayed a fenestrated endothelial cell phenotype. H5V cells overexpressing PKR2 displayed large numbers of multivesicular bodies and caveolar clusters and a disruption of the distribution of zonula occluden-1 tight junction protein. Prokineticin-2 induced the colocalization of PKR2 with Galpha(12), and activated Galpha(12), which bound to zonula occluden-1 to trigger the degradation of this protein in these cells. Prokineticin-2 induced the formation of vessel-like structures by human aortic endothelial cells expressing only PKR1, and disorganized the tight junctions in human hepatic sinusoidal endothelial cells expressing only PKR2, confirming the divergent roles of these receptors. Our findings show the functional characteristics of coronary endothelial cells depend on the expression of PKR1 and PKR2 levels and the divergent signaling pathways used by these receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20023120     DOI: 10.1152/ajpheart.00898.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  26 in total

Review 1.  The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations.

Authors:  Cecilia Martin; Ravikumar Balasubramanian; Andrew A Dwyer; Margaret G Au; Yisrael Sidis; Ursula B Kaiser; Stephanie B Seminara; Nelly Pitteloud; Qun-Yong Zhou; William F Crowley
Journal:  Endocr Rev       Date:  2010-10-29       Impact factor: 19.871

2.  Prokineticin receptor identified by phage display is an entry receptor for Trypanosoma cruzi into mammalian cells.

Authors:  K G Khusal; R R Tonelli; E C Mattos; C O Soares; B M Di Genova; M A Juliano; U Urias; W Colli; M J M Alves
Journal:  Parasitol Res       Date:  2014-10-17       Impact factor: 2.289

3.  TBX20 Regulates Angiogenesis Through the Prokineticin 2-Prokineticin Receptor 1 Pathway.

Authors:  Shu Meng; Qilin Gu; Xiaojie Yang; Jie Lv; Iris Owusu; Gianfranco Matrone; Kaifu Chen; John P Cooke; Longhou Fang
Journal:  Circulation       Date:  2018-08-28       Impact factor: 29.690

4.  Molecular characterization of EG-VEGF-mediated angiogenesis: differential effects on microvascular and macrovascular endothelial cells.

Authors:  Sophie Brouillet; Pascale Hoffmann; Mohamed Benharouga; Aude Salomon; Jean-Patrick Schaal; Jean-Jacques Feige; Nadia Alfaidy
Journal:  Mol Biol Cell       Date:  2010-06-29       Impact factor: 4.138

5.  Effects of the histone deacetylase inhibitor valproic acid on human pericytes in vitro.

Authors:  Jakob Karén; Alejandro Rodriguez; Tomas Friman; Lennart Dencker; Christian Sundberg; Birger Scholz
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

6.  Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs.

Authors:  Anat Levit; Talia Yarnitzky; Ayana Wiener; Rina Meidan; Masha Y Niv
Journal:  PLoS One       Date:  2011-11-21       Impact factor: 3.240

7.  Acute cutaneous wounds treated with human decellularised dermis show enhanced angiogenesis during healing.

Authors:  Nicholas S Greaves; Syed A Lqbal; Julie Morris; Brian Benatar; Teresa Alonso-Rasgado; Mohamed Baguneid; Ardeshir Bayat
Journal:  PLoS One       Date:  2015-01-20       Impact factor: 3.240

8.  Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1.

Authors:  Adeline Gasser; Simone Brogi; Kyoji Urayama; Toshishide Nishi; Hitoshi Kurose; Andrea Tafi; Nigel Ribeiro; Laurent Désaubry; Canan G Nebigil
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

9.  A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer.

Authors:  Valerie F Curtis; Hui Wang; Pengyuan Yang; Roger E McLendon; Xiaohan Li; Qun-Yong Zhou; Xiao-Fan Wang
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

10.  Genome-wide RNAi screening identifies genes inhibiting the migration of glioblastoma cells.

Authors:  Jian Yang; Jing Fan; Ying Li; Fuhai Li; Peikai Chen; Yubo Fan; Xiaofeng Xia; Stephen T Wong
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.